The Belgium health authority has approved Bellerophon Therapeutics‘ plans to initiate a Phase 2 clinical trial for INOpulse, the company’s pulsatile nitric oxide (NO) delivery device, to treat pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD). The decision followed data from Bellerophon’s Phase 2a study and proof…
Pulmatrix recently reported topline results from a Phase 1 pilot study evaluating PUR0200, an iSPERSE dry powder formulation incorporating a marketed long-acting and once daily bronchodilator, as a therapy for chronic obstructive pulmonary disease (COPD). Under collaborative terms and with support from the pharmaceutical company Mylan, Pulmatrix headed the pharmacokinetic…
A team of researchers at the University of North Carolina Wilmington (UNCW) is testing an exercise table that may help patients with chronic obstructive pulmonary disease (COPD) breathe easier “The most exciting thing about this team is that they are coming from all disciplines,” Justine Reel, associate dean for research and innovation…
ProterixBio, which specializes in products that aid in the development of new treatments for pulmonary conditions, including chronic obstructive pulmonary disease (COPD), announced the appointment of Fernando Martinez, MD, to its Scientific and Medical Advisory Board. “ProterixBio is thrilled to have Dr. Martinez join” the board, Grace E. Colón, PhD, ProterixBio’s…
A new practical guide titled “Managing Malnutrition in COPD” was recently launched by 10 key British professional and patient organizations to assist healthcare professionals in identifying and managing chronic obstructive pulmonary disease (COPD) in patients who are at risk of malnutrition due to their respiratory condition. The guide…
San Francisco-based biopharma Cytokinetics initiated a Phase 2 clinical trial to evaluate the effect of CK-107 on physical function in patients with chronic obstructive pulmonary disease (COPD). CK-2127107 (CK-107) is a novel fast skeletal muscle troponin activator under development as a potential therapy for COPD, spinal muscular atrophy (SMA), and other conditions. It…
Pulmatrix, a pharmaceutical company focused on developing novel inhaled drugs for lung diseases like chronic obstructive pulmonary disease (COPD), recently released an animated life sciences video to raise awareness about lung diseases and to describe promising new treatments in the company’s drug portfolio. “Millions of people struggle to breathe every…
Four Lung Institute facilities in Tampa, Scottsdale, Nashville and Pittsburg, treat restrictive and obstructive lung diseases using stem cells from the patient’s own body. Gary V., a patient, has seen his quality of life improve since he receive stem cell therapy for chronic obstructive pulmonary disease (COPD). For Gary, “improvement” is…
Results from a Novartis Pharmaceuticals Canada study to assess the company’s Ultibro Breezhaler were published in the New England Journal of Medicine. Researchers say the results are promising and expected to impact the future management and treatment of patients with chronic obstructive pulmonary disease (COPD). An article describing the findings, “…
Researchers from the University of Texas Medical Branch (UTMB) at Galveston are studying the latest trends for pulmonary rehabilitation (PR) therapy among older adults with chronic obstructive pulmonary disease (COPD). PR therapy is designed as a comprehensive approach to help patients relieve COPD symptoms and flare-ups while teaching them how…
Get regular updates to your inbox.